Biomarker-driven patient stratification has become standard practice in oncology and is spreading into other therapeutic areas, and it improves trial efficiency in exactly the way the underlying statistical logic promises. The operational cost of implementing it well is substantially higher than a simple eligibility criterion suggests.

Companion diagnostic logistics sit at the center of this complexity. A trial requiring biomarker confirmation before enrollment needs a validated testing pathway, whether through central lab testing, local lab testing with cross-validation, or a combination of both, and the turnaround time for that testing directly affects how long prospective patients wait between screening and enrollment.

Screen failure rates climb meaningfully in biomarker-stratified trials compared to broadly eligible studies, since only a subset of screened patients will carry the required biomarker. Sites and sponsors need to plan recruitment funnels accordingly, often screening several times the target enrollment number to account for this attrition, which has direct implications for site burden and overall trial timeline.

Central versus local testing decisions carry real trade-offs. Central lab testing typically offers more consistent methodology and easier regulatory defense of the enrollment criteria, but it extends the time between screening and enrollment due to sample shipping and processing, a delay that can affect patients with rapidly progressing conditions where timely enrollment genuinely matters clinically.

Retrospective biomarker testing on banked samples, for trials that stratify analysis after the fact rather than at enrollment, avoids some of this prospective operational burden but introduces its own statistical complexity around how missing or degraded samples get handled in the final analysis.

Deep Dive coverage examining how specific trials have navigated these companion diagnostic and screening funnel challenges in practice, the kind published by The Clinical Trial Vanguard, gives operations teams planning their own biomarker-driven studies a more grounded view of the real implementation costs involved.